Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Unknown 5Completed 4Active not recruiting 4Terminated 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Solid Tumor 1

Interventions

Injections 9Interviews as Topic 5Carboplatin 5Cisplatin 4toripalimab 3fludarabine 3Pemetrexed 3Iodine-125 3Immune Checkpoint Inhibitors 3Fluorodeoxyglucose F18 3tislelizumab 2envafolimab 2Specimen Handling 2Paclitaxel 2Oxaliplatin 2Drug Therapy 2Cyclophosphamide 2Cryosurgery 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1spartalizumab 1somatostatin receptor 2 1sintilimab 1regorafenib 1pembrolizumab 1osimertinib 1olaparib 1nabiximols 1malic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × spartalizumab × Other solid neoplasm × Clear all
NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2 Not yet recruiting
60 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡